<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4502">
  <stage>Registered</stage>
  <submitdate>23/06/2014</submitdate>
  <approvaldate>23/06/2014</approvaldate>
  <nctid>NCT02174822</nctid>
  <trial_identification>
    <studytitle>A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects</studytitle>
    <scientifictitle>A Phase 1, Single-center, Open-label, Sequential Drug Interaction Study Between AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [DM]/Quinidine Sulfate [Q]) and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>14-AVP-786-101</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Drug-drug Interaction</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AVP-786
Treatment: drugs - Paroxetine
Treatment: drugs - Duloxetine

Experimental: Paroxetine + AVP-786 - Paroxetine once daily orally Days 1-20. AVP-786 twice daily orally for Days 13 - 20.

Experimental: AVP-786 + paroxetine - AVP-786 twice daily orally Days 1-20. Paroxetine once daily orally for Days 9 - 20

Experimental: Duloxetine + AVP-786 - Duloxetine twice daily orally Days 1 - 13. AVP-786 twice daily orally Days 6 - 13.

Experimental: AVP-786 + duloxetine - AVP-786 twice daily orally Days 1 - 13. Duloxetine twice daily Days 9 - 13.


Treatment: drugs: AVP-786


Treatment: drugs: Paroxetine


Treatment: drugs: Duloxetine


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in plasma concentrations of paroxetine after combined dosing with AVP-786 paroxetine in healthy subjects</outcome>
      <timepoint>20 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in plasma concentration of AVP-786 (parent and metabolites) after dosing in combination with paroxetine.</outcome>
      <timepoint>20 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in plasma concentration of duloxetine after combined dosing with AVP-786</outcome>
      <timepoint>13 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in plasma concentration of AVP-786 after combined dosing with duloxetine.</outcome>
      <timepoint>13 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of adverse events (AEs) for AVP-786 and paroxetine</outcome>
      <timepoint>20 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of adverse events (AEs) for AVP-786 and duloxetine</outcome>
      <timepoint>13 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy adult males and females

          -  18 - 50 years of age

          -  BMI 18 - 30 kg/m2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  History or presence of significant disease

          -  History of substance abuse and/or alcohol abuse with the past 3 years

          -  Use of tobacco-containing or nicotine-containing products within 6 months

          -  Use of any prescription or the over-the-counter medications within 14 days</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose />
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>56</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Nucleus Network - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Avanir Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To assess steady state pharmacokinetics (PK), safety and tolerability between AVP-786
      (deuterated [d6] dextromethorphan hydrobromide [DM]/quinidine sulfate [Q]) and paroxetine and
      between AVP-786 and duloxetine.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02174822</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jason Lickliter, MBBS PhD FRACP</name>
      <address>Nucleus Network</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>